供者淋巴细胞采集前给予G-CSF可增强异基因造血干细胞移植患者的抗白血病效应
该回顾性分析纳入44例接受供者淋巴细胞输注(DLI)的异基因造血干细胞移植后患者,比较稳态DLI与G-CSF动员后DLI的效果。G-CSF-DLI组完全供者嵌合转换率更高,复发或疾病进展累积发生率更低,且移植物抗宿主病(GVHD)累积发生率未显著增加。作者认为G-CSF-DLI可产生移植物抗白血病效应而不加重GVHD,从而改善DLI后生存。
要点
- 44例患者回顾性分析比较稳态DLI与G-CSF-DLI。
- G-CSF-DLI组完全供者嵌合转换改善,复发或进展累积发生率更低。
- G-CSF-DLI未显著增加GVHD累积发生率。
核心结论
- 作者认为G-CSF-DLI可产生移植物抗白血病效应而不加重GVHD,从而改善DLI后生存。
研究设计与样本
- 回顾性分析纳入44例异基因造血干细胞移植后接受DLI以预防或治疗复发或建立完全供者嵌合的患者,比较稳态DLI与G-CSF-DLI。
主要发现
- G-CSF-DLI患者队列完全供者嵌合转换改善。
- G-CSF-DLI患者队列复发或疾病进展累积发生率更低。
- G-CSF-DLI患者队列GVHD累积发生率未显著增加。
- CD34+细胞、单核髓源性抑制细胞和单核细胞以及供者年龄和后续慢性GVHD发生被确定为显著改善DLI后总生存的风险因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor lymphocyte infusion (DLI) is an effective method to establish full donor chimerism or to prevent and treat relapse after allogeneic haematopoietic cell transplantation (allo-HCT). Usually, DLIs are collected from naïve donors as steady-state lymphocytes. When donor lymphocytes are collected during stem cell apheresis, donors are pre-treated with granulocyte colony-stimulating factor (G-CSF). However, the impact of G-CSF stimulation and the resulting composition of DLIs on beneficial anti-leukaemic responses and survival remain elusive. Therefore, we performed a retrospective analysis to evaluate the role of G-CSF-DLIs: 44 patients received either steady-state DLIs or G-CSF-DLIs to prevent and treat relapse or establish full donor chimerism after allo-HCT. The G-CSF-DLI patient cohort showed an improved conversion to full donor chimerism and a lower cumulative incidence of relapse or disease progression without a significantly increased cumulative incidence of graft-versus-host disease (GVHD). CD34+ cells, monocytic myeloid-derived suppressor cells and monocytes as well as donor age and the subsequent occurrence of chronic GVHD were identified as risk factors that significantly improve overall survival after DLI administration. In conclusion, our data suggest that administration of G-CSF-DLIs results in graft-versus-leukaemia effects without exacerbating GVHD, therefore, improving survival after DLIs.
引用
- Schneidawind C, Jahnke S, Schober-Melms I, et al. G-CSF administration prior to donor lymphocyte apheresis promotes anti-leukaemic effects in allogeneic HCT patients. Br J Haematol. 2019. PMID: 30916396. doi:10.1111/bjh.15881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。